The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033-Reference-Cited by-同舟云学术

The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033

Published:2022-06-17 Issue:5 Volume:28 Page:726-736
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

He Xiaoning¹²,Wang Xu¹²,Dong Chaohui¹,Zhao Mingyue³⁴,Wu Jing¹²

Affiliation:

1. School of Pharmaceutical Science and Technology Tianjin University Tianjin China

2. Center for Social Science Survey and Data Tianjin University Tianjin China

3. The Department of Pharmacy Administration and Clinical Pharmacy School of Pharmacy Xi'an Jiaotong University China

4. The Center for Drug Safety and Policy Research Xi'an Jiaotong University China

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14603

Reference39 articles.

1. WFH Guidelines for the Management of Hemophilia, 3rd edition

2. Economic costs of Haemophilia and the impact of prophylactic treatment on patient management;Chen SL;Am J Manag Care,2016

3. World Federation of Hemophilia.World Federation of Hemophilia report on the annual global survey 2018.https://www1.wfh.org/publications/files/pdf‐1731.pdf

4. Past, present and future of hemophilia: a narrative review

5. Prophylactic Treatment for Prevention of Joint Disease in Hemophilia — Cost versus Benefit

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Which plays a more important role in hemophilia treatment, economical development or medical technology?;2024-06-10